Unlock instant, AI-driven research and patent intelligence for your innovation.

Recombinant Fusion Proteins and Libraries from Immune Cell Repertoires

a fusion protein and immune cell technology, applied in the field of protein engineering, can solve the problems of expensive and laborious antibody drug discovery process, and the artificial generation of a representative immune repertoire from an individual with cognate paired heavy and light chain immunoglobulin or t cell receptors has not been achieved

Inactive Publication Date: 2016-12-15
GIGAGEN
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach enables the high-throughput generation of diverse recombinant immunoglobulins, allowing for the utilization of natural immune repertoires in treatment and pharmaceutical development, potentially leading to more effective and targeted therapies.

Problems solved by technology

However, the process of antibody drug discovery is expensive and tedious, and has proceeded by identification of an antigen, and then the isolation and production of antibodies with activity against the antigen.
However, artificial generation of a representative immune repertoire from an individual with cognate paired heavy and light chain immunoglobulin or T cell receptors has not been achieved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant Fusion Proteins and Libraries from Immune Cell Repertoires
  • Recombinant Fusion Proteins and Libraries from Immune Cell Repertoires
  • Recombinant Fusion Proteins and Libraries from Immune Cell Repertoires

Examples

Experimental program
Comparison scheme
Effect test

example 1

scFv Library Generation

[0158]Methods and compositions of the invention will now be discussed relative to scFv library generation.

[0159]Preparation of Beads

[0160]2× LiCl buffer was prepared as follows: For 250 mL of 2× LiCl buffer, 10 mL of 1M Tris (pH 7.5), 31.25 mL 8M LiCl, and 1 mL of 500 mM EDTA were added to 180.25 mL molecular grade water. 2× lysis buffer was prepared as follows: For each 1 mL of 2× lysis buffer, 890 μL of 2× LiCl stock, 90 μL of molecular grade water, 10 ul of 1M DTT, and 10 μL of Tween 20 were mixed to produce 1 mL solution of 2× lysis buffer.

[0161]Biotinylated IgK and IgG probes, which bind to the IgK and IgG constant regions, respectively, were synthesized with the following sequences: SEQ ID NO: 6-7. Probes were each added to 100 μL of 2× lysis buffer to a final concentration of 10 μM.

[0162]A 1 μM solution of streptavidin magnetic beads from New England Biolabs (NEB 514205) was gently rocked at room temperature for 30 minutes. 200 μL of the streptavidin ma...

example 2

Antibody Generation

[0177]Generation of Expression Constructs

[0178]An scFv library (including, e.g., SEQ ID NO: 1) was linearized by PCR using standard PCR methods and forward and reverse primers (e.g., SEQ ID NO: 4,5). An insert containing a second AOX1 promoter was synthesized by a gene synthesis vendor (IDT). A insert was then added to the circularized construct to induce expression of the full length antibody, such that the vector would now contain two AOX1 promoters, i.e., one each for heavy and light chain immunoglobulin. The new library was engineered as follows: 0.02 pmol of the linearized construct comprising the pPIC9_IgG1_scFv vector was combined with 0.04 pmol of the promoter insert (SEQ ID NO: 3) in water to a final volume of 5 μL. 5 μL of 2× Gibson Assembly Master Mix (New England Biolabs) was added to the scFv vector / promoter solution. The samples were then incubated at 50° C. for 60 minutes to generate a circularized construct of the promoter insert in the pPIC9_IgG1_...

example 3

Monoclonal Antibody Drug Discovery

[0182]Mice are immunized with a protein or other kind of antigen of interest. Single B cells from the mice are isolated and linked complexes of paired heavy and light chain variable regions are produced in vitro. B cell isolation is performed using droplet microfluidics or isolation into physical containers such as 96-well plates. The fusion construct libraries are inserted into and expressed in host cells on the surface as scFv. The engineered cells are screened for binding to sequence variants of the antigen of interest. RNA or DNA is extracted from engineered cells with binding affinity for the antigen of interest, and the RNA or DNA is sequenced to determine the immunoglobulin content of the selected cells. The linked Ig complexes amplified from the antigen-selected engineered cells are cloned en masse into plasmid vectors to produce a library of plasmid vectors comprising the recombinant fusion construct.

[0183]To study the function of these Ig ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 14 / 734,953, filed Jun. 9, 2015, incorporated herein by reference in its entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 16, 2016, is named 33889US_CRF_sequencelisting.txt and is 34,121 bytes in size.FIELD OF THE INVENTION[0003]The invention relates to methods and compositions for protein engineering for use in biomedical applications.BACKGROUND OF THE INVENTION[0004]Antibody therapeutics are increasingly used by pharmaceutical companies to treat intractable diseases such as cancer (Carter 2006 Nature Reviews Immunology 6:343-357). However, the process of antibody drug discovery is expensive and tedious, and has proceeded by identification of an antigen, and then the isolation and production of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/10C07K16/00C12Q1/68
CPCC12N15/1075C07K2317/622C07K16/00C12Q1/6876C12N15/1093C40B50/06C40B40/08C07K14/7051C12N15/1037C07K2317/14
Inventor JOHNSON, DAVID SCOTTADLER, ADAMMIZRAHI, RENA
Owner GIGAGEN